Amneal Pharmaceuticals (AMRX) announced the U.S. commercial launch of Brekiya injection, the first and only ready-to-use dihydroergotamine, DHE, autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. “We are excited to introduce Brekiya autoinjector, making this innovative therapy broadly available to healthcare providers and patients. As the first and only self-administered, ready-to-use DHE autoinjector, Brekiya offers patients the ability to treat debilitating attacks in a convenient way and avoid visits to the emergency room. With our expanding neurology portfolio, Amneal is committed to supporting providers through comprehensive education and ensuring strong patient access as we bring Brekiya autoinjector to market,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal treatment of known or suspected cyanide poisoning granted orphan status
- Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR
- Amneal Pharmaceuticals Positioned for Significant Growth with Strong Product Momentum and Strategic Advantages
- Amneal Pharmaceuticals receives FDA approval for bimatoprost ophthalmic solution
- Amneal Pharmaceuticals price target raised to $14 from $12 at JPMorgan